(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
AfD faction in western Germany ousts councilman for firebrand speech - 2'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community'
- 3Step by step instructions to Guarantee the Life span of Your Dental Inserts: Support and Care Guide
- 4Zelensky sees new Russian attack threat from Belarus
- 5Golden satellite insulation sparkles during test | Space photo of the day for Dec. 30, 2025
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- 6 Eyewear Brands Worth Purchasing
- Norovirus infections increase significantly, with positive test rates reaching 14%
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- Renewables cover over 50% of German electricity consumption in Q1
- Savvy Tips for Seniors Hyundai IONIQ EV
- Carrefour becomes first European retailer to offer shopping on ChatGPT
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
- How comfort foods trigger pleasure in our brains
